Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00491764
Recruitment Status : Completed
First Posted : June 26, 2007
Results First Posted : January 28, 2010
Last Update Posted : April 7, 2017
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Tracking Information
First Submitted Date  ICMJE June 25, 2007
First Posted Date  ICMJE June 26, 2007
Results First Submitted Date  ICMJE December 23, 2009
Results First Posted Date  ICMJE January 28, 2010
Last Update Posted Date April 7, 2017
Study Start Date  ICMJE June 2007
Actual Primary Completion Date December 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: August 30, 2013)
Complete Cure of Onychomycosis at Week 48. [ Time Frame: Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48 ]
Complete cure is defined as negative mycology (negative culture and KOH [potassium hydroxide]) and 0% nail involvement (defined as absence of onycholysis and subungual hyperkeratosis).
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: August 30, 2013)
  • Effective Treatment of Onychomycosis at Week 48. [ Time Frame: Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48 ]
    Effective treatment is defined as negative mycology (negative culture and KOH) and either 0% nail involvement or >5 mm growth of unaffected nail
  • Treatment Success of Onychomycosis at Week 48 [ Time Frame: Measured at Day 1, Week 2, Week 4, and Every 4 Weeks Thereafter Until Week 48 ]
    Treatment success was defined as negative mycology (negative culture and negative KOH) and =<10% nail involvement.
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Evaluate Efficacy and Safety of Four Posaconazole Regimens With Placebo and Terbinafine in the Treatment of Toenail Onychomycosis (Study P05082AM2)(COMPLETED)
Official Title  ICMJE An Investigator-Blinded Study Evaluating the Efficacy and Safety of Four Posaconazole Treatment Regimens With Placebo and Terbinafine in the Treatment of Onychomycosis of the Toenail
Brief Summary The purpose of this study is to evaluate the efficacy, safety, and tolerability of oral administration of four dosing regimens of posaconazole relative to placebo and terbinafine, in the treatment of toenail onychomycosis.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Condition  ICMJE Onychomycosis
Intervention  ICMJE
  • Drug: SCH 56592
    Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
    Other Names:
    • Posaconazole
    • Noxafil
  • Drug: SCH 56592
    Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
    Other Names:
    • Posaconazole
    • Noxafil
  • Drug: SCH 56592
    Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
    Other Names:
    • Posaconazole
    • Noxafil
  • Drug: SCH 56592
    Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
    Other Names:
    • Posaconazole
    • Noxafil
  • Drug: Terbinafine
    Terbinafine 250 mg QD for 12 weeks.
  • Drug: Placebo
    Placebo for 24 weeks.
Study Arms  ICMJE
  • Experimental: Posaconazole 100 mg QD for 24 weeks.
    Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
    Intervention: Drug: SCH 56592
  • Experimental: Posaconazole 200 mg QD for 24 weeks.
    Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
    Intervention: Drug: SCH 56592
  • Experimental: Posaconazole 400 mg QD for 24 weeks.
    Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
    Intervention: Drug: SCH 56592
  • Experimental: Posaconazole 400 mg QD for 12 weeks.
    Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
    Intervention: Drug: SCH 56592
  • Active Comparator: Terbinafine
    Terbinafine 250 mg QD for 12 weeks.
    Intervention: Drug: Terbinafine
  • Placebo Comparator: Placebo
    Placebo for 24 weeks.
    Intervention: Drug: Placebo
Publications * Elewski B, Pollak R, Ashton S, Rich P, Schlessinger J, Tavakkol A. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol. 2012 Feb;166(2):389-98. doi: 10.1111/j.1365-2133.2011.10660.x. Epub 2011 Dec 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 23, 2009)
218
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE December 2008
Actual Primary Completion Date December 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • The subject must meet ALL the criteria listed below for entry:

    • Subject must be between 18 and 75 years of age inclusive, of either sex, and of any race;
    • Subject must have distal subungual infection that affects approximately 25% to 75% of at least one great toenail, both clinically and mycologically diagnosed;
    • Subject must have at least 2 mm of the proximal end of the target toenail free of infection;
    • Subject must have a target toenail that is assessed as capable of growing approximately 1 mm/month, (eg, the subject needs to report cutting his or her toenails at least once per month);
    • Subject must have liver function tests within 1.5 x the upper limit of normal (bilirubin and transaminases);
    • Subject must have normal serum creatinine levels;
    • Subject must be able to take study medication orally;
    • Subject must have no history of current narcotic or alcohol addiction;
    • Subject must be willing to give written informed consent and able to adhere to dose, procedures, and visit schedules;
    • Woman of childbearing potential who is currently sexually active must agree to use a medically accepted method of contraception while receiving protocol-specified medication and for 30 days after stopping the medication. Methods include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed intrauterine device, oral or systemic hormonal contraceptive (plus an additional reliable barrier method), and surgical sterilization (eg, hysterectomy or tubal ligation).

Woman of child-bearing potential who is not currently sexually active must agree to use a medically accepted method of contraception should she become sexually active while participating in the study.

  • Woman of childbearing potential must have a negative serum pregnancy test within 72 hours prior to start of study drug.

Exclusion Criteria:

  • The subject will be excluded from entry if ANY of the criteria listed below are met:

    • Subject with one or more of the following conditions on the target toenail:

      • proximal subungual onychomycosis,
      • white superficial onychomycosis,
      • dermatophytoma or "yellow spike/streak",
      • exclusively lateral disease,
      • inability to become normal in the opinion of the investigator.
    • Subject with psoriasis, severe moccasin-type tinea pedis requiring treatment, symptomatic interdigital tinea pedis, lichen planus, or other abnormalities that could result in a clinically abnormal nail;
    • Subject with peripheral vascular disease or peripheral circulatory impairment;
    • Subject with history of uncontrolled diabetes mellitus;
    • Subject with known chronic or active liver disease;
    • Subject with any known immunodeficiency;
    • Subject with a family history of long QT syndrome;
    • Subject with an electrocardiogram with QTc interval prolongation greater than 450 msec for males and 470 msec for females;
    • Subject with potassium or magnesium lower than the lower limit of normal;
    • Subject with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study;
    • Subject who has received systemic antifungal therapy within 3 months or topical antifungal therapy applied to the foot or toenails within 1 month of study entry;
    • Subject who has received radiation therapy, chemotherapy, and/or immunosuppressive drugs within 6 months of Randomization, and/or oral corticosteroids for >1 month within the 6 months of Randomization (exception: inhaled steroids);
    • Subject using medications known to interact with azoles such as terfenadine, pimozide, quinidine, halofantrine, astemizole, alfentanil, cisapride, HMG-Co A (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors that are metabolized by CYP3A4, and ebastine, within 7 days prior to Randomization; and pravastatin within 14 days prior to Randomization;
    • Subject using medications known to lower the serum concentration/efficacy of azoles including rifampin, rifabutin, cimetidine, carbamazepine, phenytoin, barbiturates, and isoniazid, 3 doses or more within 7 days prior to Randomization;
    • Subject with a known sensitivity to azoles, POS and/or its excipients, terbinafine and/or its excipients;
    • Subject who has been previously enrolled in this study or any other POS investigational trial;
    • Subject known to have received treatment with investigational drugs within 30 days prior to enrollment into this study;
    • Woman who is breastfeeding, pregnant, or intends to become pregnant;
    • Subject who is part of the staff personnel directly involved with this study;
    • Subject who is a family member of the investigational study staff.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT00491764
Other Study ID Numbers  ICMJE P05082
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description:

http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf

http://engagezone.msd.com/ds_documentation.php

Responsible Party Merck Sharp & Dohme Corp.
Study Sponsor  ICMJE Merck Sharp & Dohme Corp.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Merck Sharp & Dohme Corp.
Verification Date March 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP